VAXGEN
VaxGen, Inc. operates as a biopharmaceutical company in the United States. It owns a biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that could be used to make cell culture or microbial biologic products.
VAXGEN
Industry:
Biotechnology
Founded:
1995-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.vaxgen.com
Total Employee:
1+
Status:
Active
Contact:
(650) 624-1000
Technology used in webpage:
SPF Nginx DOSarrest Uniregistry
Similar Organizations
Cimarron Medical
Cimarron Medical operates as a pre-clinical biopharmaceutical company in the United States.
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. operates as a biopharmaceutical company.
Stock Details
Official Site Inspections
http://www.vaxgen.com
- Host name: 86-105-245-69.haip.transip.net
- IP address: 86.105.245.69
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "VaxGen" on Search Engine
History of HIV Vaccine Research | NIAID: National Institute of …
The first large-scale HIV vaccine trial in a developing country began. VaxGen initiated a Phase 3 trial of AIDSVAX (VAX003) involving over 2,500 volunteers in Thailand. The …See details»
VaxGen - Crunchbase Company Profile & Funding
Details. Industries. Biotechnology. Headquarters Regions San Francisco Bay Area, West Coast, Western US. Founded Date 1995. Operating Status Active. Stock Symbol …See details»
AIDSVAX - Wikipedia
AIDSVAX is an experimental HIV vaccine that was developed originally at Genentech in San Francisco, California, and later tested by the VaxGen company, a Genentech …See details»
What Has 30 Years of HIV Vaccine Research Taught Us? - PMC
Oct 30, 2013 On the organizational side, the VaxGen results stimulated the search of mechanisms for a more strategic and coordinated approach to solve the HIV vaccine …See details»
An HIV Vaccine — Challenges and Prospects | NEJM
Aug 28, 2008 The initial empirical approach of immunizing with VaxGen's AIDSVax, a recombinant form of the outer glycoprotein-120 (gp120) portion of the HIV envelope, which was based on a strategy that was...See details»
The Search for Effective HIV Vaccines | NEJM
Aug 25, 2005 In February 2003, after more than a decade of work, a team of scientists representing the biotechnology company VaxGen announced the results of the first phase 3 trial to test the efficacy of a...See details»
VaxGen, Inc., Fighting the AIDS Epidemic | Stanford Graduate …
Healthcare. The VaxGen, Inc. case details the efforts of VaxGen and its president, Don Francis, to obtain approval to conduct phase III clinical trials in Thailand for AIDSVAX, …See details»
COVAX explained - GAVI
Sep 3, 2020 Coordinated by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO, COVAX will achieve this by acting as a …See details»
U.S. to launch $36 million AIDS vaccine trial - July 9, 2002 - CNN
Jul 9, 2002 BARCELONA, Spain (CNN) -- U.S. health authorities Monday announced plans to undertake a $36 million trial of an AIDS vaccine, the largest such trial to date.See details»
The business of making vaccines - PMC - National Center for ...
VaxGen (Brisbane, CA, USA) Anthrax, smallpox and bacterial meningitis: Recombinant subunit vaccines with alum-adjuvant as well as vaccinia vaccine: Development and …See details»
VaxGen Nominates Director Candidates, Clarifies Rights to AIDS …
Sep 30, 2009 VaxGen retains an option to obtain the exclusive right to manufacture, commercialize, and further develop the HIV vaccine candidates in the U.S., Europe, …See details»
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection …
Dec 3, 2009 In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox …See details»
Don Francis - Wikipedia
VaxGen. Global Solutions for Infectious Diseases. Donald Pinkston Francis (born October 24, 1942) is an American epidemiologist who worked on the Ebola outbreak in Africa in …See details»
VaxGen gains on speedy FDA review - MarketWatch
BRISBANE, Calif. (CBS.MW) -- Shares of VaxGen surged more than 20 percent Monday after federal regulators pledged to give a speedy review to the small biotech firm's …See details»
AIDS answers and questions | The Scientist Magazine®
Nov 26, 2003 | 3 min read. PDF VERSION. VaxGen's AIDSVAX vaccine, based on a recombinant gp120 coat protein, failed to prevent HIV infection or even slow the …See details»
VaxGen to Acquire diaDexus in a Stock-for-Stock Merger
Apr 14, 2010 VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can...See details»
HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, …
VaxGen (formerly Genenvax) was formed as a spin-off company from Genentech with the sole purpose of developing the gp120 vaccine. VaxGen announced in July 2002 that the …See details»
Covid-19: What do we know about Sputnik V and other Russian …
Mar 19, 2021 In August 2020, Russia’s President Vladimir Putin surprised the world by approving its first domestically developed covid-19 vaccine, before phase III clinical trials …See details»
VaxGen's Sketchy Statistics | Science | AAAS
Feb 27, 2003 When VaxGen announced the results of the first-ever efficacy trial of an AIDS vaccine on 24 February, a few sharp-eyed scientists questioned the statistical …See details»
Organization | VaxGen
Organization Overview. First Clinical Trial. 1999 NCT00006327. First Marketed Drug. None First NDA Approval. None Last Known Activity ... VaxGen (v1) | VaxGen (v2) Active Ingredients. Drugs in Phase 3 Trials (5) a244 rgp120/hiv-1 ...See details»